CUSIP 98422T100COMXLOQ4 2025
42 filings · latest Feb 17, 2026
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Gilead Sciences, Inc. | 9.11M | $5.83M |
| 2 | Bain Capital Life Sciences Investors, LLC | 7.37M | $4.72M |
| 3 | Frazier Life Sciences Management, L.P. | 5.92M | $3.79M |
| 4 | Point72 Asset Management, L.P. | 4.00M | $2.56M |
| 5 | Sio Capital Management, LLC | 2.13M | $1.37M |
| 6 | Stempoint Capital LP | 2.03M | $1.30M |
| 7 | Merck & Co., Inc. | 1.48M | $949.9K |
| 8 | Vanguard Group Inc | 1.26M | $803.6K |
| 9 |
| 4 | Feb 12, 2026 | Gilead Sciences, Inc. | 13G/A | 19.9% | 14.52M | SEC |
| 5 | Dec 11, 2025 | Coastlands Capital LP | 13G | 10.0% | — | SEC |
| 6 | Nov 14, 2025 | Stempoint Capital LP | 13G | 7.2% | 4.00M | SEC |
| 7 | Nov 14, 2025 | Point72 Asset Management, L.P. | 13G/A | 9.9% | 8.00M | SEC |
| 8 | Aug 14, 2025 | Frazier Life Sciences Public Fund, L.P. | 13G/A | 9.9% | 8.14M | SEC |
| 9 | Aug 14, 2025 | Gilead Sciences, Inc. | 13G/A | 19.9% | 10.61M | SEC |
| 10 | Jun 17, 2025 | Point72 Asset Management, L.P. | 13G | 7.2% | 4.00M | SEC |
See the full Schedule 13D/13G history for Xilio Therapeutics Inc.
Unlock full history| Empery Asset Management, LP |
| 1.18M |
| $757.4K |
| 10 | Ghisallo Capital Management LLC | 1.11M | $712.7K |